3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Squamous Cell Carcinoma of Head and Neck
2
Melanoma
2
Carcinoma, Non-Small-Cell Lung
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Irinotecan
58
Bevacizumab
56
Oxaliplatin
49
Leucovorin
49
Fluorouracil
49
Capecitabine
45
Cetuximab
44
pembrolizumab
23
IFL protocol
15
Nivolumab
11
regorafenib
10
Panitumumab
10
Celecoxib
8
Radiotherapy
7
Cyclophosphamide
7
atezolizumab
6
Surgical Procedures, Operative
6
Gemcitabine
6
Folfox protocol
6
Colonoscopy
6
trifluridine tipiracil drug combination
5
Neoadjuvant Therapy
5
Metformin
5
Immunohistochemistry
5
Biopsy
5
tislelizumab
4
spartalizumab
4
durvalumab
4
Trastuzumab
4
Mitomycin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Colorectal Neoplasms
×
Toll-Like Receptor 1
×
Clear all
NCT05576077
2025-03-10
STARLING
Turnstone Biologics, Corp.
Phase 1
Terminated
31 enrolled